Rangers confirm Youssef Chermiti faces lengthy spell out with ACL injury

Share This Article:
Youssef Chermiti faces lengthy injury spell

Rangers have confirmed that striker Youssef Chermiti will spend a significant period on the sidelines after suffering an anterior cruciate ligament (ACL) injury.

The 22-year-old forward, who has Portuguese and Tunisian roots sustained the injury during Rangers’ match against Hibernian on Sunday after colliding with the pitchside advertising boards at Ibrox.

Chermiti was forced to leave the pitch during the first half of the encounter, immediately raising concerns about the severity of the injury.

The striker was later seen leaving the stadium wearing a protective boot and knee brace, further fuelling fears that he had suffered a serious setback.

Following further medical assessment, Rangers have now confirmed the extent of the injury, revealing that Chermiti has sustained damage to his anterior cruciate ligament and faces a lengthy period away from competitive action.

The Scottish giants issued a statement confirming the unfortunate news and offering their full support to the Portuguese forward as he begins the rehabilitation process.

“Following assessment, striker Youssef Chermiti suffered an ACL injury in Sunday’s match with Hibernian. Youssef will be out of action for a significant period of time.

“Everyone at Rangers is with him as he begins his recovery.”

The injury represents a major setback for Chermiti, who had been looking to establish himself as an important attacking option for Rangers.

ACL injuries are among the most serious setbacks footballers can suffer and typically require a lengthy rehabilitation period, meaning Chermiti is now facing an extended spell away from the first team.

Rangers will now have to assess their attacking options in the absence of the young striker, while Chermiti will begin the long road back to full fitness.

The club and its supporters will be hoping for a smooth recovery as the forward begins his rehabilitation following the latest medical assessment.